Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LVGN6051 + anlotinib
- Development stage
- Unknown
- Lead developer
- Lijin Biomedical Technology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**LVGN6051 + anlotinib** is a combination therapy under clinical investigation, primarily for refractory soft tissue sarcoma. LVGN6051 is a conditional 4-1BB (CD137) agonistic monoclonal antibody that preferentially activates immune responses in the tumor microenvironment by binding to Fc gamma receptor IIB, enhancing T cell activation and antitumor immunity. Anlotinib is an oral, small-molecule multi-targeted tyrosine kinase inhibitor that potently suppresses tumor angiogenesis and proliferation by inhibiting receptor tyrosine kinases including VEGFR-1/2/3, FGFR1-4, PDGFR-α/β, and c-Kit. Their combination aims to synergize immunostimulatory and anti-angiogenic activities for improved control of advanced cancers, notably sarcomas. The regimen is under investigation in phase 1b/2 trials for safety and efficacy in patients with refractory or metastatic soft tissue sarcoma.[3][5]
- Other names
- LVGN6051 plus anlotinibLVGN-6051 plus anlotinibLVGN 6051 plus anlotinibLVGN6051 combined with anlotinibLVGN-6051 combined with anlotinibLVGN 6051 combined with anlotinib
02
Targets
TNFRSF9 (CD137 extracellular domain)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)FGFR4 (Fibroblast growth factor receptor 4)
Beyond the preview
Go deeper on LVGN6051 + anlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LVGN6051 + anlotinib.